Budget impact evaluation of the DAPA-HF trial: is dapagliflozin cost-saving for the treatment of heart failure with reduced ejection fraction?
29 June 2021 (08:00 - 23:59)
Organised by:
Abstract
Slides
About the speaker
Health Economics and Outcomes Research Ltd, Cardiff (United Kingdom of Great Britain & Northern Ireland)
738 More presentations in this session
Assistant Professor N. Radovanovic (Belgrade, RS)
Assistant Professor V. Kirillova (Ekaterinburg, RU)
Access the full session
The Event
Heart Failure 2021
29 June 2021
08:00 CET
You may be interested in
Congress Session
Congress Presentation
